Version 2.5.2.0 CRISP Logo CRISP Homepage Help for CRISP Email Us

Abstract

Grant Number: 5R44GM061445-04
Project Title: Protein Stability and Functionality Enhancement Method
PI Information:NameEmailTitle
LIETZ, ERIC ejlietz@genopsys.com PRESIDENT

Abstract: DESCRIPTION (provided by applicant): The long range goal of this research is to develop the directed evolution platform technology termed Insertion, Deletion, Substitution random mutagenesis (ids.PCR) for commercial applications in diagnostics. We propose to develop diagnostic reporter enzymes for diagnosis and therapeutic monitoring that require sensitive, specific, quantitative and multiplexed detection of target proteins present in complex mixtures. We will generate beta-lactamase variants that contain inserted amino acid sequences with binding affinity for specific disease-associated target proteins. These functionally enhanced "Diagnostic Reporter Enzymes" will combine the highly efficient catalytic activity of beta-lactamase with specific antibody-like binding affinities, resulting in rapid, specific, selective, and sensitive detection of biological markers associated with disease. For this Phase II research, two commercially relevant protein targets will be used to screen and characterize the evolved enzymes for response to the target alone and in complex patient samples. PROPOSED COMMERCIAL APPLICATIONS: Ids.PCR is a platform evolution technology that has far-reaching potential commercial applications. The demonstration of diagnostic reporter enzymes evolved using this technology would have widespread application in diagnostics and therapeutic monitoring. The goal is to ultimately use these low-cost single molecule reagents to screen large numbers of biological markers for analysis of human diseases in complex patient samples.

Thesaurus Terms:
beta lactamase, biomarker, chemical stability, clinical chemistry, directed evolution, enzyme activity, polymerase chain reaction, reagent /indicator, technology /technique development
chemical substitution, cost effectiveness, enzyme substrate, gene deletion mutation, high throughput technology, peptide chemical synthesis, protein sequence, transposon /insertion element, vascular endothelial growth factor
biotechnology, genetic library

Institution: GENOPSYS, INC.
SOQUEL, CA 95073
Fiscal Year: 2006
Department:
Project Start: 01-MAR-2001
Project End: 31-JAN-2008
ICD: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
IRG: ZRG1


CRISP Homepage Help for CRISP Email Us